文献速递神经肿瘤

无功能垂体大腺瘤内镜经鼻手术后的长期结局

Long-term outcomes after endoscopic endonasal surgery for nonfunctioning pituitary macroadenomas.
PubMed 文献 · J Neurosurg · 2020-01-31

该回顾性研究纳入2003—2014年接受内镜经鼻手术治疗的无功能垂体大腺瘤患者190例,随访至少5年。全切后10年复发概率为4.7%,需治疗概率为1.6%;次全切后10年进展概率为24.5%,需额外治疗概率为21%。作者认为次全切后观察或可避免不必要的预防性放疗。

要点

  • 全切后10年复发概率4.7%,需治疗概率仅1.6%。
  • 次全切后10年进展概率24.5%,需额外治疗概率21%。
  • 肿瘤体积>1 cm3、Knosp评分≥3、Ki-67≥3%或可提示密切随访。

核心结论

  • 全切后10年复发概率低,需治疗概率更低。
  • 次全切后即使不放疗,10年需干预概率仅约20%,观察期或可避免不必要的预防性放疗。
  • 肿瘤体积>1 cm3、Knosp评分≥3、Ki-67≥3%或可用于提示密切随访或早期预防性放疗。

研究设计与样本

  • 回顾性分析本机构2003—2014年接受内镜经鼻手术治疗的无功能垂体大腺瘤患者数据库。
  • 仅纳入术后随访至少5年的患者,共190例,平均年龄63.8±13.2岁,女性79例(41.6%)。
  • 肿瘤体积在术前和术后MRI上测量;全切后出现0.1 cm3肿瘤体积定义为复发,次全切后残留肿瘤增加25.0%定义为进展。

主要发现

  • 平均随访75.0±18.0个月,全切127例(66.8%)。
  • 多因素分析中,年龄(p=0.04)、术前肿瘤体积(p=0.03)、Knosp评分(p<0.001)和Ki-67(p=0.03)是次全切的显著预测因素。
  • 全切患者5年和10年复发概率分别为3.9%和4.7%,需治疗复发概率分别为0.79%和1.6%。
  • 次全切63例中,6例(9.5%)接受早期术后放疗且未进展,其余57例(90.5%)观察;观察者5年和10年进展概率分别为21%和24.5%,需额外治疗概率分别为17.5%和21%。
  • 全组复发或进展的预测因素为Knosp评分(p<0.001)和Ki-67升高(p=0.03);未接受早期放疗的次全切患者中,进展的显著预测因素为海绵窦位置(p<0.05)和肿瘤大小>1.0 cm3(p=0.005)。

临床怎么用

  • 全切后10年复发概率低,需治疗概率更低。
  • 次全切后即使不放疗,10年需干预概率仅约20%,观察期或可避免不必要的预防性放疗(作者认为)。
  • 肿瘤体积>1 cm3、Knosp评分≥3、Ki-67≥3%或可用于提示密切随访或早期预防性放疗(作者认为)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Nonfunctioning pituitary adenomas are benign, slow-growing tumors. After gross-total resection (GTR) or subtotal resection (STR), tumors can recur or progress and may ultimately require additional intervention. A greater understanding of long-term recurrence and progression rates following complete or partial resection and the need for further intervention will help clinicians provide meaningful counsel for their patients and assist data-driven decision-making. METHODS: The authors retrospectively analyzed their institutional database for patients undergoing endoscopic endonasal surgery (EES) for nonfunctioning pituitary macroadenomas (2003-2014). Only patients with follow-up of at least 5 years after surgery were included. Tumor volumes were measured on pre- and postoperative MRI. Tumor recurrence was defined as the presence of a 0.1-cm3 tumor volume after GTR, and tumor progression was defined as a 25.0% increase in residual tumor after STR. RESULTS: A total of 190 patients were included, with a mean age of 63.8 ± 13.2 years; 79 (41.6%) were female. The mean follow-up was 75.0 ± 18.0 months. GTR was achieved in 127 (66.8%) patients. In multivariate analysis, age (p = 0.04), preoperative tumor volume (p = 0.03), Knosp score (p < 0.001), and Ki-67 (p = 0.03) were significant predictors of STR. In patients with GTR, the probability of recurrence at 5 and 10 years was 3.9% and 4.7%, and the probability of requiring treatment for recurrence was 0.79% and 1.6%, respectively. In 63 patients who underwent STR, 6 (9.5%) received early postoperative radiation and did not experience progression, while the remaining 57 (90.5%) were observed. Of these, the probability of disease progression at 5 and 10 years was 21% and 24.5%, respectively, and the probability of requiring additional treatment for progression was 17.5% and 21%. Predictors of recurrence or progression in the entire group were Knosp score (p < 0.001) and elevated Ki-67 (p = 0.03). Significant predictors of progression after STR in those who did not receive early radiotherapy were cavernous sinus location (p < 0.05) and tumor size > 1.0 cm3 (p = 0.005). CONCLUSIONS: Following GTR for nonfunctioning pituitary adenomas, the 10-year chance of recurrence is low and the need for treatment even lower. After STR, although upfront radiation therapy may prevent progression, even without radiotherapy, the need for intervention at 10 years is only approximately 20% and a period of observation may be warranted to prevent unnecessary prophylactic radiation therapy. Tumor volume > 1 cm3, Knosp score ≥ 3, and Ki-67 ≥ 3% may be useful metrics to prompt closer follow-up or justify early prophylactic radiation therapy.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Gerges MM, Rumalla K, Godil SS, et al. Long-term outcomes after endoscopic endonasal surgery for nonfunctioning pituitary macroadenomas. J Neurosurg. 2020. PMID: 32005016. doi:10.3171/2019.11.JNS192457

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。